Navigation Links
TGen Drug Development partners with Imaging Endpoints for comprehensive clinical trial services
Date:6/9/2011

SCOTTSDALE, Ariz. June 9, 2011 TGen Drug Development (TD2) and Imaging Endpoints have teamed up to enable the rapid development of anti-cancer drugs and deliver them faster to patients in need, the companies announced today.

"The highest quality medical imaging provided by Imaging Endpoints is one more weapon in TD2's arsenal," said Dr. Stephen Gately, President of TD2, which assists drug developers in navigating the regulatory maze involved in the successful completion of clinical trials and bringing new therapeutics to market. "Our relationship is meant to help combine the best available technologies."

Imaging Endpoints will assist TD2 in the design and implementation of medical imaging analyses. Imaging Endpoints' expertise in anatomic and functional imaging will allow drug developers to best incorporate imaging into their clinical trials: probing molecular drug targets, assessing biologic responses and evaluating drug effectiveness.

"We hope that, through our new relationship with TD2, we will be able to assist oncology drug developers to maximize their return on investment in medical imaging during the course of their early-phase clinical trials," said Ron Korn, Medical Director of Imaging Endpoints. "Significant resources and time can be saved through wise and appropriate implementation of medical imaging."

The rapid completion of often time-consuming and costly clinical trials is needed to speed new treatments to the patients who need them, Dr. Gately said.

Scottsdale Mayor Jim Lane hailed the announcement by TD2 and Imaging Endpoints: "The partnership announced today between TD2 and Imaging Endpoints represents the merging of talents between two premier Scottsdale companies, and helps cement TD2 as a cornerstone of Scottsdale's growing biomedical industry."

Imaging holds the potential to predict outcomes, shorten the time needed to evaluate if a drug is hitting its target, and do so with relatively low risk to patients. By using specific imaging techniques, researchers can assess if new drug compounds are effective in such areas as anti-proliferation, metabolism and hypoxia.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related biology news :

1. Study finds widespread stream biodiversity declines at low levels of urban development
2. Development of a FRET sensor for real-time imaging of intracellular redox dynamics
3. Developmental disease is recreated in an adult model
4. Ulcer bacteria may contribute to development of Parkinsons disease
5. A study will enable the survival and growth of the 3 development phases of the European eel
6. Building brains: An introduction to neural development
7. Gene variant linked with development of COPD in men
8. Scientists find new class of compounds with great potential for research and drug development
9. New organic catalyst should enhance drug research and development
10. Brain development goes off track as vulnerable individuals develop schizophrenia
11. Study: Pace of brain development still strong in late teens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology: